Abstracts Archive - Page 1097 of 2425 - ACR Meeting Abstracts

Abstract Number: 1386 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Work Productivity and Activity As Well As Quality of Life in Patients with Rheumatoid Arthritis (RA), Psoriasis Arthritis (PsA) and Axial Spondyloarthritis (axSpA): Interim Results from a Non-Interventional Study in Austria (Go Active)
Christian Dejaco¹, Thomas Mueller², Omid Zamani, MD³, Ulrike Kurtz, MD⁴, Stefan Egger, MD⁵, Johannes Resch Passini, MD⁶, Anna Totzauer, MD⁷, Wolfgang Eisterer⁸, Babak Yazdani-Biuki, MD, Univ.Doc.⁹, Thomas Schwingenschloegl, MD¹⁰, Peter Peichl, MD. Univ.Doc. Msc¹¹, Angelika Kraus¹², Gerhard Naerr, PhD¹³ and Verena Rickert, MD. MBA¹⁴, ¹Rheumatology and Immunology, Medical University Graz, Graz, Austria, ²Private Office Dr. Thomas Mueller, Graz, Austria, ³Rheuma Zentrum Favoriten, Vienna, Austria, ⁴Rheuma Praxis Dr. Kurtz, Gleisdorf, Austria, ⁵Ordination Gesundheitsquadrat, Vienna, Austria, ⁶Rheumatology Department, Rheuma-Zentrum Wien-Oberlaa GmbH, Vienna, Austria, ⁷Private Office Dr. Anna Totzauer, Gmuend, Austria, ⁸Department of Hematology and Internal Oncology, KLINIKUM- KLAGENFURT am WÖRTHERSEE, Klagenfurt, Austria, ⁹Dr. Schrenk & Dr. Yazdani-Biuki OG - Gruppenpraxis, Fuerstenfeld, Austria, ¹⁰Private Office Dr. Thomas Schwingenschloegl, Wiener Neudorf, Austria, ¹¹Private Office Prim. Univ. Doz. Dr. Peter Peichl, MSc, Vienna, Austria, ¹²Private Office, Private Office Angelika Kraus, Melk, Austria, ¹³Medical Affairs, Merck Sharp & Dohme GmbH, Vienna, Austria, ¹⁴Medical Affairs, Merck Sharp&Dohme GmbH, Vienna, Austria
Background/Purpose: Golimumab has shown clinical efficacy and tolerability within its clinical trial program. No systematic outcome data regarding patient‐reported outcomes and health economic parameters reflecting…
Abstract Number: 1387 • 2018 ACR/ARHP Annual Meeting
Fatigue in Patients with Rheumatoid Arthritis As Compared to Different Groups of Cancer Patients
Jens Gert Kuipers¹, Michael Koller², Ulrich Rueffer³, Florian Zeman², Karolina Mueller⁴ and Joachim Weis⁵, ¹Clinic for Internal Rheumatology, Red Cross Hospital Bremen, Bremen, Germany, ²Center of Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ³German Fatigue Society, Cologne, Germany, ⁴Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ⁵University Clinic Centre Freiburg, Freiburg, Germany
Background/Purpose: Fatigue is a common symptom in patients with rheumatoid arthritis (RA) as well as patients with cancer. Fatigue considerably reduces the quality of life…
Abstract Number: 1388 • 2018 ACR/ARHP Annual Meeting
Characteristics and Symptom Severity in 21,101 Patients Reporting Systemic Lupus Erythematous in the Patientslikeme Online Health Community
Elisabeth Nyman¹, Edward R. Hammond², Timothy Vaughan³, Barnabas Desta², Xia Wang², Volkan Barut⁴ and Cathy Emmas⁵, ¹Advanced Analytics Centre, AstraZeneca, Gothenburg, Sweden, ²AstraZeneca, Gaithersburg, MD, ³PatientsLikeMe, Boston, MA, ⁴Global Medical Affairs, AstraZeneca, Cambridge, United Kingdom, ⁵Patient Centricity, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: Online health communities and research networks such as PatientsLikeMe (PLM) provide important insight into understanding chronic diseases, including systemic lupus erythematous (SLE). We aimed…
Abstract Number: 1389 • 2018 ACR/ARHP Annual Meeting
Depression and the Patient Reported Outcomes Measurement Information System in Systemic Lupus Erythematosus
Brett Dietz¹, Patricia Katz¹, Maria Dall'Era², Louise Murphy³, Cristina Lanata¹, Laura Trupin¹ and Jinoos Yazdany², ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Health-related quality of life (HRQoL) is reduced in SLE. Depression is a possible contributor to reduced HRQoL. The relationship between major depression and HRQoL…
Abstract Number: 1390 • 2018 ACR/ARHP Annual Meeting
Impact of Psoriatic Arthritis from the Patient’s Perspective in the Context of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire: An Online Global Survey
Laura C. Coates¹, Ana-Maria Orbai², Valderilio F Azevedo³, Joseph C Cappelleri⁴, Jade Moser⁵, Ralph Lippe⁶, Irwin Lim⁷, Lihi Eder⁸, Pascal Richette⁹, Meng-Yu Weng¹⁰, Rubén Queiro¹¹ and Lara Fallon¹², ¹University of Oxford, Oxford, United Kingdom, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Universidade Federal do Paraná, Curitiba, Brazil, ⁴Pfizer Inc, Groton, CT, ⁵The Harris Poll, Rochester, NY, ⁶Pfizer Pharma GmbH, Berlin, Germany, ⁷BJC Health, Sydney, Australia, ⁸Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ⁹Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ¹⁰Department of Internal Medicine, Division of Allergy, Immunology and Rheumatology, National Cheng Kung University Medical College and Hospital, Tainan, Taiwan, ¹¹Rheumatology Division, HUCA, Oviedo, Spain, ¹²Pfizer Canada, Montreal, QC, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a complex disease with high impact on quality of life (QoL). The PsA core domain set1 includes pain, patient (pt)…
Abstract Number: 1391 • 2018 ACR/ARHP Annual Meeting
Patient-Acceptable Symptom State in Psoriatic Arthritis: Prevalence and Associated Factors in Real Clinical Practice
Rubén Queiro¹, Juan Cañete², Carlos Alberto Montilla-Morales³ and Miguel A. Abad⁴, ¹Rheumatology Division, HUCA, Oviedo, Spain, ²Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ³Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, ⁴FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain
Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are remission or low disease activity. We know little about whether these objectives correlate well with a patient-acceptable…
Abstract Number: 1392 • 2018 ACR/ARHP Annual Meeting
Decreased Injection Site Pain Associated with New Etanercept Formulation in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Stanley Cohen¹, Ahmed Samad², Elaine Karis², Bradley S. Stolshek², Mona Trivedi², Hao Zhang², Girish A. Aras², Greg Kricorian² and James Chung², ¹Metroplex Clinical Research Center, Dallas, TX, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Injection site pain (ISP) is a component of the patient experience with injectable drugs. A new formulation of etanercept was developed to reduce ISP.…
Abstract Number: 1393 • 2018 ACR/ARHP Annual Meeting
Fatigue in Men and Women with Psoriatic Arthritis: An International Qualitative Study
Ana-Maria Orbai¹, Suzanne Grieb², Lilian van Tuyl³, Penelope Palominos⁴, Ying Ying Leung⁵, Karen Schipper⁶, Willemina Campbell⁷, Jessica Walsh⁸, Katherine Clegg Smith⁹, Laure Gossec¹⁰, Tania Gudu¹¹, Premarani Sinnathurai¹², Lyn March¹³, Soumya M. Reddy¹⁴, Xin Xiao Hui¹⁵, Clifton O. Bingham III¹⁶, Ricardo M. Xavier¹⁷ and Maarten de Wit¹⁸, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins Bayview Medical Center, Center for Child and Community Health Research, Baltimore, MD, ³Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, ⁵North District Hospital, Hong Kong, China, ⁶VU University, Amsterdam, Netherlands, ⁷Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁸University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, ⁹Health, Behavior and Society, Johns Hopkins University Bloomberg School of Public Health, Batimore, MD, ¹⁰Sorbonne Universités, Paris, France, ¹¹University of Medicine Carol Davila Bucuresti, Romania, Bucuresti, Romania, ¹²Rheumatology, University of Sydney, Sydney, Australia, ¹³Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ¹⁵Rheumatology, Singapore General Hospital, Singapore, Singapore, ¹⁶Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Universidade Federal do Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil, ¹⁸EULAR standing committee of PARE, Zurich, Switzerland
Background/Purpose: Fatigue is prevalent and important to people with psoriatic arthritis (PsA)1. Women with PsA have worse symptom and life impact scores than men, including…
Abstract Number: 1394 • 2018 ACR/ARHP Annual Meeting
Development and Pilot of a Patient Satisfaction Scale in Rheumatology
Antonia Valenzuela¹, Khushboo Sheth², Stanford Shoor², Philip L. Ritter² and Kate Lorig³, ¹Immunology and Rheumatology, Stanford University, Palo Alto, CA, ²Immunology & Rheumatology, Stanford University, Palo Alto, CA, ³Stanford University, Palo Alto, CA
Background/Purpose: Patient satisfaction has been studied as a performance improvement measure in clinical practice among patients with a variety of diseases, but to date there…
Abstract Number: 1395 • 2018 ACR/ARHP Annual Meeting
Could the Shortening of the Electronic Osteoarthritis Knee and Hip Quality of Life (OAKHQOL) Questionnaire Improve Its Metric Properties?
Maud Wieczorek¹, Christine Rotonda¹, Jonathan Epstein^1,2, Francis Guillemin^1,2 and Anne-Christine Rat^1,3, ¹Université de Lorraine, EA4360, APEMAC, Nancy, France, ²Inserm, CIC-1433 Epidémiologie Clinique, Vandoeuvre-lès-Nancy, France, ³Rheumatology Department, CHRU Nancy, Vandoeuvre-lès-Nancy, France
Background/Purpose: The aim of this study was to assess the validity of a short version of the electronic OAKHQOL questionnaire in a combined analysis with…
Abstract Number: 1396 • 2018 ACR/ARHP Annual Meeting
Factors Associated with Specific Quality of Life Evolution in SLE Patients: A French Prospective Longitudinal Multicenter Study
Hervé Devilliers¹, Marie Corneloup², Francois Maurier³, Denis Wahl^4,5, Geraldine Muller⁶, Olivier Aumaître⁷, Pascal Sève⁸, Gilles Blaison⁹, Jean-Loup Pennaforte¹⁰, Thierry Martin¹¹, Nadine Magy¹², Sabine Berthier¹³, Laurent Arnaud¹⁴, Abderrahmane Bourredjem¹⁵ and Zahir Amoura¹⁶, ¹Service de Médecine Interne et Maladies Systémiques, CHU de Dijon, Dijon, France, ²Clinical epidemiology, Clinical investigation center, INSERM CIC-EC 1432, Dijon University Hospital, 21000 Dijon, France, ³Médecine interne, Hôpitaux Privés de Metz, Metz, France, ⁴CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, ⁵CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, ⁶Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁷CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁸Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁹Internal medicine departement, Colmar Hospital, Colmar, France, ¹⁰Internal Medicine, Internal medicine departement, CHU de Reims, Reims, France, ¹¹Cnrs UPR9021, Department of Clinical Immunology and Internal Medicine, Strasbourg University Hospital, IBMC CNRS UPR9021, Strasbourg, France, ¹²Internal Medecine, CHRU Besançon, Besancon, France, ¹³Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ¹⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ¹⁵Clinical investigation center, INSERM CIC-EC 1432, Dijon University Hospital, Dijon, France, ¹⁶Université Pierre et Marie Curie, Paris, France
Background/Purpose: To analyze variables associated with evolution of disease-specific health related quality of life (HRQoL) in systemic lupus erythematosus (SLE) patients. Methods: We conducted a…
Abstract Number: 1397 • 2018 ACR/ARHP Annual Meeting
Item Responses to Disease-Specific Quality of Life Questionnaires in the 18 Months Following a Flare in SLE: An Item Response Theory Analysis of a French Prospective Longitudinal Multicenter Study
Marie Corneloup¹, Francois Maurier², Denis Wahl³, Geraldine Muller⁴, Olivier Aumaître⁵, Pascal Sève⁶, Gilles Blaison⁷, Jean-Loup Pennaforte⁸, Thierry Martin⁹, Nadine Magy¹⁰, Sabine Berthier¹¹, Laurent Arnaud¹², Abderrahmane Bourredjem¹³, Zahir Amoura¹⁴ and Hervé Devilliers¹⁵, ¹Clinical epidemiology, Clinical investigation center, INSERM CIC-EC 1432, Dijon University Hospital, 21000 Dijon, France, ²Médecine interne, Hôpitaux Privés de Metz, Metz, France, ³CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, ⁴Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ⁶Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁷Internal medicine departement, Colmar Hospital, Colmar, France, ⁸Internal Medicine, Internal medicine departement, CHU de Reims, Reims, France, ⁹Internal medicine and clinical immunology departement, Strasbourg University Hospital, Strasbourg, France, ¹⁰Internal Medecine, CHRU Besançon, Besancon, France, ¹¹Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ¹²Department of Rheumatology, Hôpitaux Universitaires de Strasbourg; INSERM UMR-S 1109, Strasbourg, France, ¹³Clinical investigation center, INSERM CIC-EC 1432, Dijon University Hospital, Dijon, France, ¹⁴Department of Internal Medicine, National referral center for systemic lupus erythematosus and anti-phospholipid syndrome, Pitie-Salpetriere University Hospital, Paris, France, ¹⁵Service de Médecine Interne et Maladies Systémiques, CHU de Dijon, Dijon, France
Background/Purpose: To explore, at an item-level, the effect of disease activity (DA) on disease specific health related quality of life (HRQoL) factors in systemic lupus…
Abstract Number: 1398 • 2018 ACR/ARHP Annual Meeting
Inflammatory Arthritis DMARD Adverse Effects Are Pervasive and Can Greatly Impact Quality of Life and Work and Social Roles: Initial Results from the Omeract Safety Working Group
Kathleen M. Andersen¹, Ayano Kelly², Anne Lyddiatt³, Clifton O. Bingham III⁴, Vivian P. Bykerk⁵, Marita Cross⁶, Adena Batterman⁷, Joan Westreich⁸, Lyn March⁹, Michelle Jones¹⁰, Beverly Shea¹¹, Peter Tugwell¹², Peter Brooks¹³, Lee S. Simon¹⁴, Robin Christensen¹⁵ and Susan J. Bartlett¹⁶, ¹Department of Family Medicine, McGill University, Montreal, QC, Canada, ²Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, Australia, ³Musculoskeletal Group, Cochrane Collaboration, Hamilton, ON, Canada, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Deptartment of Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Institute of Bone and Joint Research–Kolling Institute, University of Sydney, Sydney, Australia, ⁷Social Work Programs, Hospital for Special Surgery, New York, NY, ⁸Department of Social Work Programs, Hospital for Special Surgery, New York, NY, ⁹Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹⁰Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹University of Ottawa, Ottawa, ON, Canada, ¹²Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ¹³The University of Melbourne, Victoria, Australia, ¹⁴SDG LLC Consulting, West Newton, MA, ¹⁵Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, ¹⁶Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada
Background/Purpose: There is suboptimal reporting of adverse events (AE) in trials. The OMERACT Safety Working Group is developing a patient-centered AE collection and reporting approach…
Abstract Number: 1399 • 2018 ACR/ARHP Annual Meeting
Assessing a Conceptual Framework of Quality of Life in a Cutaneous Lupus Erythematosus Population
Motolani E. Ogunsanya¹, Andrew Hudson², Rebecca Vasquez³ and Benjamin F. Chong³, ¹College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Texas Tech University Health Sciences Center, Lubbock, TX, ³Dermatology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: In order to better discern medication efficacy for CLE, a better understanding of CLE’s impact on quality of life (QoL) in individuals with CLE…
Abstract Number: 1400 • 2018 ACR/ARHP Annual Meeting
Effects of Childhood-Onset SLE on Academic Achievements and Employment in Adult Life
Noortje Groot¹, Marc Bijl², Radboud J. E. M. Dolhain³, Els J. Zirkzee⁴, Ruth D.E. Fritsch-Stork⁵, Y.K. Onno Teng⁶, Karina de Leeuw⁷, Irene E.M. Bultink⁸ and Sylvia S.M. Kamphuis⁹, ¹Paediatric Rheumatology, Erasmus Medical Centre - Sophia Children's Hospital, Rotterdam, Netherlands, ²Internal Medicine and Rheumatology, Martini Hospital, Groningen, Netherlands, ³Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁵Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ⁷Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁸Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁹Pediatric Rheumatology, Sophia Children's Hospital – Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: To investigate the effects of cSLE on education, vocation and employment in a large cohort of adults with cSLE. Methods: Patients were seen by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].